Photochemical activation of MH3-B1/rGel: a HER2-targeted treatment approach for ovarian cancer

Bente Bull-Hansen; Maria B. Berstad; Kristian Berg; Yu Cao; Ellen Skarpen; Ane Sofie Fremstedal; Michael G. Rosenblum; Qian Peng; Anette Weyergang

doi:10.18632/oncotarget.3814

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Photochemical activation of MH3-B1/rGel: a HER2-targeted treatment approach for ovarian cancer

Bente Bull-Hansen, Maria B. Berstad, Kristian Berg, Yu Cao, Ellen Skarpen, Ane Sofie Fremstedal, Michael G. Rosenblum, Qian Peng and Anette Weyergang _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2015; 6:12436-12451. https://doi.org/10.18632/oncotarget.3814

Metrics: PDF 1900 views | HTML 3296 views | ?

Abstract

Bente Bull-Hansen1, Maria B. Berstad1, Kristian Berg1, Yu Cao2,5, Ellen Skarpen3, Ane Sofie Fremstedal1, Michael G. Rosenblum2, Qian Peng4 and Anette Weyergang1

1 Department of Radiation Biology, Institute for Cancer Research, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway

2 Immunopharmacology and Targeted Therapy Laboratory, Department of Experimental Therapeutics, M.D. Anderson Cancer Center, Houston, TX, USA

3 Department of Biochemistry, Institute for Cancer Research, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway

4 Department of Pathology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway

5 Current address: The Scripps Research Institute, Department of Chemistry, La Jolla, CA, USA

Correspondence to:

Anette Weyergang, email:

Keywords: ovarian cancer, HER2/neu/ErbB2, immunotoxin, photochemical internalization, photodynamic

Received: October 13, 2014 Accepted: March 11, 2015 Published: April 14, 2015

Abstract

HER2-targeted therapy has been shown to have limited efficacy in ovarian cancer despite frequent overexpression of this receptor. Photochemical internalization (PCI) is a modality for cytosolic drug delivery, currently undergoing clinical evaluation. In the present project we studied the application of PCI in combination with the HER2-targeted recombinant fusion toxin, MH3-B1/rGel, for the treatment of ovarian cancer. The SKOV-3 cell line, resistant to trastuzumab- and MH3-B1/rGel- monotherapy, was shown to respond strongly to PCI of MH3-B1/rGel to a similar extent as observed for the treatment-sensitive SK-BR-3 breast cancer cells. Extensive hydrolytic degradation of MH3-B1/rGel in acidic endocytic vesicles was indicated as the mechanism of MH3-B1/rGel resistance in SKOV-3 cells. This was shown by the positive Pearson’s correlation coefficient between Alexa488-labeled MH3-B1/rGel and Lysotracker in SKOV-3 cells in contrast to the negative Pearson’s correlation coefficient in SK-BR-3 cells. The application of PCI to induce the release of MH3-B1/rGel was also demonstrated to be effective on SKOV-3 xenografts. Application of PCI with MH3-B1/rGel was further found highly effective in the HER2 expressing HOC-7 and NuTu-19 ovarian cancer cell lines. The presented results warrant future development of PCI in combination with MH3-B1/rGel as a novel therapeutic approach in preclinical models of ovarian cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 3814

Publication Alerts

Research Papers:

Photochemical activation of MH3-B1/rGel: a HER2-targeted treatment approach for ovarian cancer

Abstract